MBCC 2010 header

Publication
Article

Exclusive coverage of the 27th annual Miami Breast Cancer Conference includes expert perspectives, abstract reviews, interviews and more.

Perspective and Highlights from the 27th Annual Miami Breast Cancer Conference

Clinical quandary in adjuvant chemo: Endpoint versus toxicity

“Father of tamoxifen” foresees challenges and successes for endocrine therapy

More Coverage from MBCC 2010

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content